Insider Selling: Medpace Holdings Inc (NASDAQ:MEDP) CEO Sells 47,106 Shares of Stock
Medpace Holdings Inc (NASDAQ:MEDP) CEO August J. Troendle sold 47,106 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $123.99, for a total transaction of $5,840,672.94. Following the completion of the transaction, the chief executive officer now directly owns 616,643 shares of the company’s stock, valued at $76,457,565.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ:MEDP opened at $119.35 on Friday. Medpace Holdings Inc has a twelve month low of $58.72 and a twelve month high of $144.49. The company has a market cap of $4.23 billion, a price-to-earnings ratio of 39.31 and a beta of 1.22. The stock has a fifty day simple moving average of $96.91 and a 200-day simple moving average of $88.75. The company has a current ratio of 0.94, a quick ratio of 0.89 and a debt-to-equity ratio of 0.16.
Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 27th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.28. Medpace had a return on equity of 16.05% and a net margin of 12.11%. The business had revenue of $205.00 million during the quarter, compared to the consensus estimate of $181.17 million. During the same period last year, the company earned $0.81 earnings per share. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. As a group, equities research analysts predict that Medpace Holdings Inc will post 3.21 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. Fortis Advisors LLC bought a new stake in shares of Medpace during the first quarter worth $30,000. Private Capital Group LLC lifted its position in shares of Medpace by 162.4% during the first quarter. Private Capital Group LLC now owns 858 shares of the company’s stock worth $63,000 after purchasing an additional 531 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of Medpace during the first quarter worth $64,000. Sandy Spring Bank bought a new stake in shares of Medpace during the first quarter worth $65,000. Finally, Allred Capital Management LLC bought a new stake in shares of Medpace during the first quarter worth $87,000. Institutional investors and hedge funds own 79.83% of the company’s stock.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.